DLBCL is a suspected disease in the field of blood tumors, with complex clinical performance and often involving multi-system congestion. Early identification and standardised clinical care are critical to improving prognosis. The diagnosis of the disease requires a combination of clinical performance, imaging, laboratory testing and pathological activation.
The platform can help align national and international authorities with teams to provide accurate diagnosis and treatment programs. In recent years, with the development of treatment-oriented, immune-regulatory therapy and precision medicine, many previously difficult-to-treat blood tumour diseases have been significantly improved. Treatment requires close monitoring of efficacy and adverse reactions and timely adjustment according to changes in the disease.
Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of chronic inflammation-related DLBCL. 2. Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment programs; 3.
Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.